AU7050091A - Vaccine and immunoserum against drugs of abuse - Google Patents
Vaccine and immunoserum against drugs of abuse Download PDFInfo
- Publication number
- AU7050091A AU7050091A AU70500/91A AU7050091A AU7050091A AU 7050091 A AU7050091 A AU 7050091A AU 70500/91 A AU70500/91 A AU 70500/91A AU 7050091 A AU7050091 A AU 7050091A AU 7050091 A AU7050091 A AU 7050091A
- Authority
- AU
- Australia
- Prior art keywords
- drugs
- fact
- vaccine
- drug
- procedure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 95
- 239000003814 drug Substances 0.000 title claims abstract description 95
- 229960005486 vaccine Drugs 0.000 title claims abstract description 39
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims abstract description 11
- 229960003920 cocaine Drugs 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 17
- 229940125717 barbiturate Drugs 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 230000002163 immunogen Effects 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 229940127240 opiate Drugs 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 229940125723 sedative agent Drugs 0.000 claims description 4
- 239000000932 sedative agent Substances 0.000 claims description 4
- 230000001078 anti-cholinergic effect Effects 0.000 claims description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 2
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 229940049706 benzodiazepine Drugs 0.000 claims description 2
- 235000005607 chanvre indien Nutrition 0.000 claims description 2
- 244000261228 chanvre indien Species 0.000 claims description 2
- 229960002803 methaqualone Drugs 0.000 claims description 2
- 229960002715 nicotine Drugs 0.000 claims description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000006227 byproduct Substances 0.000 claims 1
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 238000011146 sterile filtration Methods 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract description 4
- 108010078791 Carrier Proteins Proteins 0.000 abstract description 4
- 230000000638 stimulation Effects 0.000 abstract description 3
- 230000000857 drug effect Effects 0.000 abstract description 2
- 208000030507 AIDS Diseases 0.000 abstract 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 abstract 1
- 229960002069 diamorphine Drugs 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 31
- 229960005181 morphine Drugs 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 13
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000003993 interaction Effects 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 235000019504 cigarettes Nutrition 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- -1 effedrine Chemical compound 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 229940097042 glucuronate Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229950002454 lysergide Drugs 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KCYXYAIVKQSDFP-WMRVMTBBSA-N 2-[[(4r,4ar,7s,7ar,12bs)-7-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-9-yl]oxy]acetic acid Chemical compound O[C@H]([C@@H]1O2)C=C[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(OCC(O)=O)=CC=C1C4 KCYXYAIVKQSDFP-WMRVMTBBSA-N 0.000 description 1
- RVCMQOUQLRUENR-XSFUTMHBSA-N 4-[[(4r,4ar,7s,7ar,12bs)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-yl]oxy]-4-oxobutanoic acid Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(=O)CCC(O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O RVCMQOUQLRUENR-XSFUTMHBSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- JMBQKKAJIKAWKF-UHFFFAOYSA-N Glutethimide Chemical compound C=1C=CC=CC=1C1(CC)CCC(=O)NC1=O JMBQKKAJIKAWKF-UHFFFAOYSA-N 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SIDLZWOQUZRBRU-UHFFFAOYSA-N Methyprylon Chemical compound CCC1(CC)C(=O)NCC(C)C1=O SIDLZWOQUZRBRU-UHFFFAOYSA-N 0.000 description 1
- WAEXKFONHRHFBZ-ZXDZBKESSA-N Morphine-3-glucuronide Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O WAEXKFONHRHFBZ-ZXDZBKESSA-N 0.000 description 1
- GNJCUHZOSOYIEC-GAROZEBRSA-N Morphine-6-glucuronide Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)O)O[C@@H]1[C@]52CCN3C)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O GNJCUHZOSOYIEC-GAROZEBRSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 150000001398 aluminium Chemical class 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229940040544 bromides Drugs 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 229960002972 glutethimide Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229960000316 methyprylon Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000000945 opiatelike Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003868 paraldehyde Drugs 0.000 description 1
- SQYNKIJPMDEDEG-UHFFFAOYSA-N paraldehyde Chemical compound CC1OC(C)OC(C)O1 SQYNKIJPMDEDEG-UHFFFAOYSA-N 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- CTRLRINCMYICJO-UHFFFAOYSA-N phenyl azide Chemical class [N-]=[N+]=NC1=CC=CC=C1 CTRLRINCMYICJO-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical class C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH2720/90 | 1990-08-22 | ||
| CH2720/90A CH678394A5 (enrdf_load_stackoverflow) | 1990-08-22 | 1990-08-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU7050091A true AU7050091A (en) | 1992-03-17 |
Family
ID=4240096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU70500/91A Abandoned AU7050091A (en) | 1990-08-22 | 1991-01-17 | Vaccine and immunoserum against drugs of abuse |
Country Status (8)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6210677B1 (en) | 1993-01-29 | 2001-04-03 | Robert C. Bohannon | Method to reduce the physiologic effects of drugs on mammals |
| EP0812593B8 (en) * | 1993-03-23 | 2010-11-10 | SmithKline Beecham Biologicals S.A. | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
| ES2287379T3 (es) * | 1995-03-31 | 2007-12-16 | Xenova Research Limited | Conjugados de hapteno-transportador para usar en terapia del abuso de drogas. |
| US5840307A (en) * | 1995-03-31 | 1998-11-24 | Immulogic Pharmacuetical Corp. | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation |
| AU776410B2 (en) * | 1995-03-31 | 2004-09-09 | Xenova Research Limited | Hapten-carrier conjugates for use in drug-abuse therapy |
| US5876727A (en) * | 1995-03-31 | 1999-03-02 | Immulogic Pharmaceutical Corporation | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| US6063908A (en) * | 1996-07-02 | 2000-05-16 | Roche Diagnostics Corporation | Reagents for lysergic acid diethylamide immunoassay |
| KR100538388B1 (ko) * | 1996-09-30 | 2005-12-22 | 지노버 리서치 리미티드 | 약물남용 치료시에 사용되는 불완전항원-담체 포합체 및 상기 포합체의 제조방법 |
| SE9801923D0 (sv) * | 1998-05-29 | 1998-05-29 | Independent Pharmaceutical Ab | Nicotine vaccine |
| US6232082B1 (en) | 1998-12-01 | 2001-05-15 | Nabi | Hapten-carrier conjugates for treating and preventing nicotine addiction |
| AU2001255537A1 (en) * | 2000-04-20 | 2001-11-07 | The Board Of Trustees Of The University Of Arkansas | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs |
| US7202348B2 (en) * | 2000-04-20 | 2007-04-10 | The University Of Arkansas For Medical Sciences | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs |
| US6669937B2 (en) * | 2000-04-20 | 2003-12-30 | The Board Of Trustees Of The University Of Arkansas | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs |
| US7632929B2 (en) | 2000-04-20 | 2009-12-15 | The Board Of Trustees Of The University Of Arkansas | Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof |
| AU5723001A (en) | 2000-04-24 | 2001-11-07 | Aryx Therapeutics | Ultrashort acting hypnotic barbiturates |
| RU2326693C2 (ru) | 2002-07-18 | 2008-06-20 | Цитос Байотекнолоджи Аг | Конъюгаты гаптен-носитель и их применение |
| MXPA04006617A (es) | 2004-07-07 | 2006-01-12 | Inst Nac De Psiquiatria Ramon | Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina. |
| ES2415655T3 (es) | 2006-06-15 | 2013-07-26 | The Board Of Trustees Of The University Of Arkansas | Anticuerpos monoclonales que reconocen selectivamente Metanfetamina y compuestos similares a Metanfetamina |
| EP2140263B1 (en) | 2007-04-20 | 2017-01-04 | The Board of Trustees of The University of Arkansas | Hapten compounds and compositions and uses thereof |
| US9023353B2 (en) | 2013-03-13 | 2015-05-05 | The Board Of Trustees Of The University Of Arkansas | Anti-(+)—methamphetamine monoclonal antibodies |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4375414A (en) * | 1971-05-20 | 1983-03-01 | Meir Strahilevitz | Immunological methods for removing species from the blood circulatory system and devices therefor |
| US3766162A (en) * | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4045420A (en) * | 1973-05-29 | 1977-08-30 | Syva Company | Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof |
| US4053459A (en) * | 1975-09-24 | 1977-10-11 | Hoffmann-La Roche Inc. | Antibody specific to methaqualone and its metabolites |
| SU792869A1 (ru) * | 1979-03-30 | 1982-03-30 | Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений | Способ получени конъюгированных антигенов барбитурова кислота-иммуногенный носитель |
| SU1123704A1 (ru) * | 1983-04-08 | 1984-11-15 | Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений | Способ получени конъюгированных антигенов |
| DE3884731D1 (de) * | 1987-10-09 | 1993-11-11 | Ube Industries | Monoklonaler Antikörper gegen Methamphetamin, seine Herstellung, Testverfahren und Testsatz für Methamphetamin. |
| EP0363041A1 (en) * | 1988-09-21 | 1990-04-11 | Ube Industries, Ltd. | Monoclonal antibody to morphine, preparation of monoclonal antibody, assaying kit and assaying method of morphine |
-
1990
- 1990-08-22 CH CH2720/90A patent/CH678394A5/de not_active IP Right Cessation
-
1991
- 1991-01-17 AU AU70500/91A patent/AU7050091A/en not_active Abandoned
- 1991-01-17 DE DE59107814T patent/DE59107814D1/de not_active Expired - Lifetime
- 1991-01-17 CA CA002067205A patent/CA2067205C/en not_active Expired - Lifetime
- 1991-01-17 JP JP3502013A patent/JPH05502871A/ja active Pending
- 1991-01-17 AT AT91901668T patent/ATE137977T1/de active
- 1991-01-17 EP EP91901668A patent/EP0496839B2/de not_active Expired - Lifetime
- 1991-01-17 WO PCT/CH1991/000016 patent/WO1992003163A1/de active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP0496839B1 (de) | 1996-05-15 |
| CA2067205A1 (en) | 1992-02-23 |
| WO1992003163A1 (de) | 1992-03-05 |
| CA2067205C (en) | 2009-10-27 |
| DE59107814D1 (de) | 1996-06-20 |
| ATE137977T1 (de) | 1996-06-15 |
| JPH05502871A (ja) | 1993-05-20 |
| EP0496839A1 (de) | 1992-08-05 |
| EP0496839B2 (de) | 2004-03-03 |
| CH678394A5 (enrdf_load_stackoverflow) | 1991-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6699474B1 (en) | Vaccine and immunserum against drugs of abuse | |
| CA2067205C (en) | Vaccine and immune serum against drugs of abuse | |
| CA2267456C (en) | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | |
| DE69327587T2 (de) | Konjugate von schwach immunogenen antigenen und synthetischen peptidträgern und impfstoffe diese enthaltend | |
| US8357375B2 (en) | Process for the preparation and use of a bivalent vaccine against morphine-heroine addiction | |
| US5871747A (en) | Antigen-carrying microparticles and their use in the indication of humoral or cellular responses | |
| US20060239997A1 (en) | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | |
| HUP0104365A2 (hu) | Nikotinfüggőség kezelésére és megelőzésére alkalmas haptén-hordozó konjugátumok, azokat tartalmazó vakcinák és gyógyászati készítmények a kojugátumokra válaszként termelődő antitest és alkalmazásuk | |
| US4816253A (en) | Novel mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent | |
| US20100015172A1 (en) | Method to reduce the physiologic effects of drugs on mammals | |
| DE69637089T2 (de) | Hapten-Träger-Konjugate zur Anwendung in der Drogen-Missbrauchs-Therapie | |
| US4567041A (en) | Mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent | |
| IL98935A (en) | Liposomal immunogenic carriers | |
| US20120171239A1 (en) | Immunogenic Conjugates for Producing Immune Responses to Drugs of Abuse and Methods of Use | |
| US20060058220A1 (en) | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | |
| JP2004514655A (ja) | ジスルフィド架橋環化ペプチドを含むワクチン免疫原およびそのアレルギー治療への使用 | |
| Liu et al. | Immunologic tolerance to allergenic protein determinants: properties of tolerance induced in mice treated with conjugates of protein and a synthetic copolymer of D-glutamic acid and D-lysine (D-GL) | |
| Stollar et al. | Nucleoside specificity in the carrier IgG-dependent induction of tolerance | |
| Elson et al. | Activation of cholera toxin-specific T cells in vitro | |
| US4296097A (en) | Suppression of reaginic antibodies to drugs employing polyvinyl alcohol as carrier therefor | |
| RU2548802C1 (ru) | Иммуноген для лечения и профилактики зависимости от опиатов | |
| Burdon | Present status of the cellular and humoral theories of anaphylaxis | |
| Meulbroek | Enhancement of the antibody response to a polysaccharide-based vaccine by synthesizing an artificial glycoprotein and using a novel microcapsule delivery system | |
| WO1995009650A1 (en) | Albumin-conjugated tumour cell-free extracts, antigenic compositions comprising the same, related antibodies, and uses thereof | |
| HK1027293B (en) | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |